The market isn't built for children with cancer, this is how we propose to change it
Introducing C-Further’s multi-stakeholder analysis: “Shaping a new market for children and young people with cancer”.
Nearly half of childhood tumours carry a change that could, in principle, be drugged. Yet children still wait years longer than adults for new targeted treatments, because developing a drug costs about the same regardless of who the patient is, but the market at the end is far smaller. This paper explains why the market has failed, and how philanthropic, public and private capital could change that.
~50%

paediatric tumours carrying a potentially druggable change
~$880m

to develop one new drug, whatever the disease
6.5 years

median wait for a first-in-child trial (if any) after the first-in-adult trial
What’s inside:
Cancer is the leading cause of death from illness in children and young people.
New tailored and well-tolerated treatments are urgently needed.
Childhood cancer is a structural market failure, not necessarily a scientific one.
Existing incentives are necessary but insufficient.
Models to bridge and scale early-stage, child-first drug discovery already exist and need to scale.
Fully overcoming the market failure requires matching ambition at the next stage of drug development.
…and more.

Philanthropic and public funding, deployed strategically, with expert input from both academia and industry, can help incentivise private investment and close this historic gap.
We’re preparing a 2027 consultation to turn this proposal into a broader coalition.